PO.MCB07.03 · 分子与细胞生物学

鸟苷素基因位点的蛋白质组学揭示了结直肠癌中GUCY2C激素沉默背后的Wnt/beta-catenin调控因子

Proteomics at the guanylin gene locus reveals Wnt/beta-catenin regulatory factors underlying GUCY2C hormone silencing in colorectal cancer

海报缩略图:鸟苷素基因位点的蛋白质组学揭示了结直肠癌中GUCY2C激素沉默背后的Wnt/beta-catenin调控因子
编号 5946 展板 1 时间 4/21 02:00–05:00 区域 Section 22 主讲 Adi Caspi, BS
分会场 Mechanisms and Dynamics of Gene Expression
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Adi Caspi1, Ariana A. Entezari1, Jasmine R. Alvarez1, Annie K. Londregan1, Thomas J. M. Kuret1, Jeffrey A. Rappaport2, Adam E. Snook1, Scott A. Waldman1

1Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA,2Department of Medicine, Johns Hopkins University, Baltimore, MD

摘要 Abstract

中文摘要
鸟苷素(GUCA2A)是一种在结肠上皮中表达的旁分泌激素,可激活跨膜受体鸟苷酸环化酶C(GUCY2C)。激活的GUCY2C通过cGMP信号促进液体分泌、基因组稳定性、屏障完整性和稳态。在早期结直肠癌(CRC)中,鸟苷素表达普遍受到抑制,使GUCY2C信号级联沉默并促成肿瘤发生。鸟苷素的抑制在转录水平上由GUCA2A基因上游一个Wnt敏感增强子处异常的Wnt/beta-catenin/TCF4信号所介导。使用Wnt诱导型CRC细胞系中的无偏蛋白质组学,我们试图直接鉴定介导鸟苷素表达对Wnt敏感性并在肿瘤发生背景下控制其转录沉默的调控因子。将靶向GUCA2A调控元件(由启动子和增强子组成)的sgRNA与dCas9-APEX2融合蛋白偶联,以捕获所需的DNA位点。ChIP-qPCR和ChIP-seq证实了sgRNA在靶向GUCA2A方面的有效性和特异性。进行APEX2介导的邻近生物素化以标记与靶位点相关的蛋白质。链霉亲和素亲和下拉随后进行基于LC-MS/MS的蛋白质组学,揭示了在Wnt开启和Wnt关闭条件下GUCA2A启动子处差异富集的候选调控蛋白,包括先前鉴定的Wnt调节的鸟苷素激活因子p38alpha(MAPK14)。此外,其他候选者无论Wnt状态如何均在启动子处富集,提示对鸟苷素的调控要么是Wnt非依赖的,要么需要Wnt信号下游的翻译后控制。本分析中鉴定的鸟苷素表达的潜在调控因子正在使用敲低筛选结合GUCA2A荧光素酶报告基因进行验证,目标是鉴定CRC中鸟苷素缺失背后的调控机制。由于GUCY2C作为抑癌因子发挥作用,对鸟苷素转录沉默机制的新见解将提供机会来指导预防和治疗策略,以修复该信号通路并对抗疾病。
查看英文原文 English abstract
Guanylin (GUCA2A) is a paracrine hormone expressed in the colonic epithelium that activates the transmembrane receptor guanylyl cyclase C (GUCY2C). Activated GUCY2C promotes fluid secretion, genome stability, barrier integrity, and homeostasis through cGMP signaling. In early colorectal cancer (CRC), guanylin expression is universally suppressed, silencing the GUCY2C signaling cascade and contributing to tumorigenesis. Repression of guanylin is mediated transcriptionally by aberrant Wnt/beta-catenin/TCF4 signaling at a Wnt-sensitive enhancer upstream of the GUCA2A gene. Using unbiased proteomics in Wnt-inducible CRC cell lines, we sought to directly identify regulators that mediate Wnt sensitivity to guanylin expression and control its transcriptional silencing in the context of tumorigenesis. sgRNAs targeting the GUCA2A regulatory element, consisting of the promoter and enhancer, were coupled to a dCas9-APEX2 fusion protein to capture the desired DNA locus. ChIP-qPCR and ChIP-seq confirmed sgRNA effectiveness and specificity in targeting GUCA2A . APEX2-mediated proximity biotinylation was performed to label proteins associated with the targeted site. Streptavidin affinity pulldown followed by LC-MS/MS-based proteomics revealed candidate regulatory proteins differentially enriched at the GUCA2A promoter under Wnt-on and Wnt-off conditions, including the previously identified Wnt-modulated guanylin activator p38alpha (MAPK14). Additionally, other candidates were enriched at the promoter irrespective of Wnt status, suggesting regulation of guanylin that is either Wnt-independent or requires post-translational control downstream of Wnt signaling. Potential regulators of guanylin expression identified in this analysis are undergoing validation using a knockdown screen in combination with a GUCA2A luciferase reporter with the goal of identifying the regulatory machinery underlying guanylin loss in CRC. As GUCY2C functions as a tumor suppressor, new insights into the mechanism of guanylin transcriptional silencing will provide an opportunity to inform prevention and treatment strategies to repair the signaling pathway and oppose disease.
利益披露 Disclosure
A. Caspi, None.. A. A. Entezari, None. J. R. Alvarez, 10x Genomics ). A. K. Londregan, None.. T. J. M. Kuret, None.. J. A. Rappaport, None. A. E. Snook, Targeted Diagnostics & Therapeutics, Inc. Stock Option, Patent, Other Intellectual Property. Vittoria Biotherapeutics, Inc. Employment, Stock, Stock Option, ), Travel, Patent, Other Intellectual Property. S. A. Waldman, Targeted Diagnostics & Therapeutics, Inc. ), Other, Founder, Board of Directors, Scientific Advisory Board.

← 返回 AACR 2026 检索